5J3 Stock Overview A medical technology company, develops and sells point-of-care platforms that utilizes electrical impedance spectroscopy for the evaluation of skin disorders in Europe, the United States, North America, Asia, Oceania, and internationally. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
SciBase Holding AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for SciBase Holding Historical stock prices Current Share Price SEK 0.021 52 Week High SEK 0.061 52 Week Low SEK 0.0002 Beta 1.5 1 Month Change 28.05% 3 Month Change -21.05% 1 Year Change -56.25% 3 Year Change -96.04% 5 Year Change n/a Change since IPO -93.31%
Recent News & Updates
New minor risk - Profitability Nov 17 SciBase Holding AB (publ) to Report Q3, 2025 Results on Nov 07, 2025
Third quarter 2024 earnings released: kr0.081 loss per share (vs kr0.11 loss in 3Q 2023) Nov 13
Scibase Holding AB (Publ) Announces Positive Findings in Case Study Monitoring Treatment Outcomes in Atopic Dermatitis Patient Nov 13 SciBase Holding AB (publ), Annual General Meeting, May 21, 2025
Second quarter 2024 earnings released: kr0.081 loss per share (vs kr0.095 loss in 2Q 2023) Aug 22 See more updates
New minor risk - Profitability Nov 17 SciBase Holding AB (publ) to Report Q3, 2025 Results on Nov 07, 2025
Third quarter 2024 earnings released: kr0.081 loss per share (vs kr0.11 loss in 3Q 2023) Nov 13
Scibase Holding AB (Publ) Announces Positive Findings in Case Study Monitoring Treatment Outcomes in Atopic Dermatitis Patient Nov 13 SciBase Holding AB (publ), Annual General Meeting, May 21, 2025
Second quarter 2024 earnings released: kr0.081 loss per share (vs kr0.095 loss in 2Q 2023) Aug 22
SciBase Holding AB (publ) Appoints Leda Beaty as Head of US Commercial Operations Jun 14
New minor risk - Profitability Jun 05
Forecast to breakeven in 2026 Jun 04
Now 87% undervalued after recent price drop Jun 04
New major risk - Shareholder dilution May 31
Scibase Announces the Launch of Ebarrier Score, the First Ai-Driven Skin Barrier Assessment Tool for Research and Cosmetic Testing May 29
New minor risk - Shareholder dilution May 29
Now 94% undervalued after recent price drop May 16 SciBase Holding AB (publ) has completed a Composite Units Offering. May 11
New major risk - Financial position Feb 22
Full year 2023 earnings released: kr0.52 loss per share (vs kr0.63 loss in FY 2022) Feb 22
New major risk - Revenue and earnings growth Nov 13
Third quarter 2023 earnings released: kr0.11 loss per share (vs kr0.13 loss in 3Q 2022) Nov 12 SciBase Holding AB (publ) to Report Fiscal Year 2023 Results on Feb 21, 2024
SciBase Holding AB (publ) to Report Q1, 2024 Results on May 09, 2024 Nov 10
SciBase Holding AB (publ), Annual General Meeting, May 17, 2024 Nov 03
SciBase Holding AB (publ) Appoints Nomination Committee Nov 02
New major risk - Market cap size Oct 24
SciBase Holding AB Announces the Publication of A Collaborative Scientific Project with the Swiss Institute of Allergy and Asthma Research in Davos, Switzerland Sep 29 Scibase Appoints Pia Renaudin as Chief Executive Officer
Second quarter 2023 earnings released: kr0.095 loss per share (vs kr0.14 loss in 2Q 2022) Aug 20
SciBase Holding AB (publ) Announces Executive Changes May 16
Full year 2022 earnings released: kr0.63 loss per share (vs kr0.67 loss in FY 2021) Apr 25
Full year 2022 earnings released: kr0.63 loss per share (vs kr0.67 loss in FY 2021) Feb 14 SciBase Holding AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023
SciBase Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023 Nov 10
SciBase Holding AB (publ) Announces New Study Shows Nevisense Significantly Improves US Clinician's Decision-Making Beyond Dermoscopy Oct 26
SciBase Holding AB (publ), Annual General Meeting, May 18, 2023 Oct 08
SciBase Holding AB Announces Nevisense Detects Skin Barrier Damage in Mice Caused by Household Detergents Sep 01
Second quarter 2022 earnings released: kr135 loss per share (vs kr0.19 loss in 2Q 2021) Aug 19
SciBase Holding AB (publ) to Report Q3, 2022 Results on Nov 10, 2022 Jun 01
SciBase Holding AB (publ) Announces US Study Shows That EIS and Nevisense Significantly Improves Clinicians' Diagnostic Accuracy May 17
SciBase Holding AB (publ) Study Shows Clinical Benefit of Nevisense May 02
Full year 2021 earnings released: kr0.67 loss per share (vs kr1.12 loss in FY 2020) Apr 27
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Third quarter 2021 earnings released: kr0.13 loss per share (vs kr0.20 loss in 3Q 2020) Nov 14
Second quarter 2021 earnings released: kr0.19 loss per share (vs kr0.38 loss in 2Q 2020) Aug 20
SciBase Holding AB (publ) announced that it has received SEK 71.214109 million in funding from Van Herk Investments B.V., Ostvast Capital Management Limited, and other investors Jun 01
First quarter 2021 earnings released: kr0.15 loss per share (vs kr0.54 loss in 1Q 2020) May 14 Scibase Receives Important European MDR Certification
SciBase Holding AB (publ) Submits First Reimbursement Application to CMS in Florida May 04
David Melin Resigns as Head of Product Development of SciBase AB Mar 09
Full year 2020 earnings released: kr1.12 loss per share (vs kr2.38 loss in FY 2019) Feb 21
Revenue beats expectations Feb 21 SciBase Holding AB (publ) to Report Q3, 2021 Results on Nov 11, 2021
SciBase Holding AB (publ) Announces New Study Published Validating Further Nevisense Indication, Non-Melanoma Skin Cancer Dec 10
New 90-day high: €0.41 Nov 27
Third quarter 2020 earnings released: kr0.20 loss per share Nov 13 SciBase Holding AB (publ) to Report Fiscal Year 2020 Results on Feb 19, 2021 Scibase Holding AB (Publ) Announces Positive Step for US Reimbursement of Nevisense
SciBase Holding Releases Next Generation Platform, Nevisense Go Nov 02
Earnings released Aug 21 Shareholder Returns 5J3 DE Medical Equipment DE Market 7D 69.4% 0.9% 1.3% 1Y -56.3% -9.7% 9.0%
See full shareholder returns
Return vs Market: 5J3 underperformed the German Market which returned 10.1% over the past year.
Price Volatility Is 5J3's price volatile compared to industry and market? 5J3 volatility 5J3 Average Weekly Movement 223.5% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 5J3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5J3's weekly volatility has decreased from 1086% to 223% over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 1998 30 Pia Renaudin scibase.com
SciBase Holding AB (publ), a medical technology company, develops and sells point-of-care platforms that utilizes electrical impedance spectroscopy for the evaluation of skin disorders in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin cancer; and assess skin barrier and inflammation.
Show more SciBase Holding AB (publ) Fundamentals Summary How do SciBase Holding's earnings and revenue compare to its market cap? 5J3 fundamental statistics Market cap €7.68m Earnings (TTM ) -€5.59m Revenue (TTM ) €2.34m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 5J3 income statement (TTM ) Revenue SEK 26.87m Cost of Revenue SEK 7.45m Gross Profit SEK 19.43m Other Expenses SEK 83.63m Earnings -SEK 64.20m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
Earnings per share (EPS) -0.29 Gross Margin 72.29% Net Profit Margin -238.93% Debt/Equity Ratio 0%
How did 5J3 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 08:32 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources SciBase Holding AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Christian Lee Pareto Securities Mats Hyttinge Redeye
Show 0 more analysts 
